Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-05-30
1999-06-08
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A61K 3170
Patent
active
059104848
ABSTRACT:
The present invention is based on the unexpected discoveries that hypothalamic inhibitory factor (HIF) has a positive inotropic effect in a whole organ preparation, such as an isolated perfused heart, and that HIF, to a greater extent than ouabain, dilates the coronary arteries in the isolated perfused heart as manifested in increased coronary flow in hearts treated with HIF. The present invention relates to a method for increasing coronary perfusion in a mammalian host comprising administering to the host in need thereof an effective amount of hypothalamic inhibitory factor (HIF). The invention also relates to a method for producing an increased coronary vasodilatory effect in a mammalian host comprising administering to a mammalian host in need thereof an effective amount of HIF. The method of the present invention can be used to prevent and/or treat ischemic cardiac malfunction and coronary artery restenosis.
REFERENCES:
patent: 4551426 (1985-11-01), Freytag et al.
patent: 4665019 (1987-05-01), Hamlyn et al.
patent: 4780314 (1988-10-01), Graves
patent: 5164296 (1992-11-01), Blaustein et al.
patent: 5429928 (1995-07-01), Blaustein et al.
patent: 5716937 (1998-02-01), Haupert, Jr.
Sergio, B. et al., "Effects of an Endogenous Ouabainlike Compound on Heart and Aorta", Hypertension, 17(6): Part 2:944-950 (1991).
Mathews, W.R. et al., "Mass Spectral Characterization of an Endogenous Digitalis-Like Factor From Human Plasma", Hypertension, 17(6): Part 2:930-935 (1991).
Ludens, J.H. et al., "Purification of an Endogenous Digitalis-like Factor From Human Plasma for Structural Analysis", Hypertension, 17(6): Part 2: 923-929 (1991).
Hamlyn, J.M. et al., "Identification and Characterization of a ouabain-like Compound from Human Plasma", Proc. Natl. Acad. Sci. USA, 88:6259-6263 (1991).
Haber, E. and Haupert, Jr., G.T., "The Search for a Hypothalamic Na, K-ATPase Inhibitors", Hypertension, 9:315-324 (1987).
Haupert, Jr., G.T., "Overview: Physiological Inhibitors of Na, K-ATPase Concept and Status", The Na.sup.+, K.sup.+ -Pump Part B: Cellular Aspects, 297-320 (1988).
Mudgett-Hunter, M. et al., "High-Affinity Monoclonal Antibodies to the Cardiac Glycoside, Digoxin", J. Immunol., 129(3):1165-1172 (1982).
Carilli, C.T. et al., "Hypothalamic Factor Inhibits the (Na,K) ATPase from the extracellular Surface", J. Biol.Chem., 260(2):1027-1031 (1985).
Janssens, S.P. et al., "Hypothalamic Na.sup.+, K.sup.+ -ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats", J. Cardio. Pharm., 22(Suppl. 2): S42-S46 (1993).
Haupert, Jr., G.T. and Sancho, J.M., "Sodium transport inhibitor from bovine hypothalamus", Proc. Natl. Acad. Sci. USA, 76(9):4658-4660 (1979).
Haupert, Jr., G.T. et al., "Hypothalamic sodium-transport inhibitor is a high affinity reversible inhibitor of Na.sup.+ -K.sup.+ -ATPase", reprint from Am. Physiol. Soc, 247:F919-F924 (1984).
Mudgett-Hunter, M. et al., "Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies", Mol. Imunol., 22(4):477-488 (1985).
Smith, T.W. et al., "Treatment of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments", The New England Journal of Medicine, 307(22):1357-1362 (1982).
Smith, T.W. et al., "Reversal of Advanced Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies", The New England Journal of Medicine, 294(15):797-800 (1976).
Hallaq, H.A. and Haupert, Jr., G.T., "Positive inotropic effects of the endogenous Na.sup.+ /K.sup.+ -transporting ATPase Inhibitor form the hypothalamus,", Proc. Natl. Acad. Sci. USA, 86:10080-10084 (1989).
Axelrod, J., "J. Methylation reactions in the Formation and Metabolism of Catecholamines and Other Biogenic Amines", Pharm. Rev., 18(1): Part I:95-113 (1966).
Thomas, R. et al., "Synthesis and Biological Activity of Semisynthetic Digitalis Analogs", J. Pharm. Sci., 63(11):1649-1683 (1974).
Hoffman, B.F. and Bigger, Jr., J.T., "Chapter 34: Digitalis and Allied Cardiac Glycosides", The Pharmacological Basics for Therapeutics, (NY: Pergamon Press): 814-839 (1990).
Haupert, Jr., G.T. et al. "Target Organ Sensitivity to an Endogenous Na, K-ATpase Inhibitor from Hypothalamus", Kidney Int., 31:435A (1987).
Weinberg, U. et al., "Identification and Preliminary Characterization of Two Human Digitalis-Like Substances that are Structurally Related to Digoxin and Ouabain", Biochem. & Biophys. Res. Comm., 188(3):1024-1029 (1992).
Tamura, M. et al., "Isolation and Characterization of a Specific Endogenous Na.sup.+, K.sup.+ -ATPase Inhibitor from Bovine Adrenal", Biochem., 27:4244-4253 (1988).
Schoner, W. et al., "Purification and Properties of Endogenous Ouabain-like Substances from Hemofiltrate and Adrenal Glands", J. Cardiovas. Pharm., 22(Suppl. 2):S29-S31 (1993).
Lewis, L.K. et al., "Ouabain Is Not Detectable in Human Plasma", Hypertension24(5) :549-555 (1994).
Valdes, Jr., R. & Graves S.W. "Protein Binding of Endogenous Digoxin-Immunoactive Factors in Human Serum and Its Variation with Clinical Condition", J. Clin. Endoc. Metab., 60(6):1135-1143 (1985).
Illescas, M. et al., "Complete purification of two identical Na.sup.+ -pump inhibitors isolated from bovine hypothalamus and hypophysis", FEBS Let., 261(2):436-440 (1990).
Zhao,N. et al., "Na,K-ATPase Inhibitors from Bovine Hypothalamus and Human Plasma Are Different from Ouabain: Nanogram Scale CD Structural Analysis", Biochem., 34:9893-9896 (1995).
Tymiak et al., "Physicochemical Characterization of a Ouabain Isomer Isolated from Bovine Hypothalamus", Proc. Natl. Acad. Sci., 90:8189-8193 (1993).
Nakanishi et al., "Search for an Endogenous Mammalian Cardiotonic Factor", Saponins Used in Traditional and Modern Medicine, pp. 219-224 (1996).
Anner et al., "Hypothalamic Na.sup.+ -K.sup.+ -ATPase Inhibitor Characterized in Two-Sided Liposomes Containing Pure Renal Na.sup.+ -K.sup.+ -ATPase", Am. J. Physiol., 258 (Renal Fluid Electrolyte Physiol., 27):F144-F153 (1990).
Kohn, R., et al., "Endogenous Digitalis-Like Factor in Patients with Acute Myocardial Infarction," Cor Vasa, 34(3):227-237 1992).
Delva, P., et al., "Increase in Plasma Digitalis-Like Activity During Percutaneous Transluminal Coronary Angioplasty in Patients with Coronary Stenosis," Life Sci., 47(5): 385-389 (1990).
Goldberg Jerome D.
The General Hospital Corporation
LandOfFree
Treatment of ischemic cardiac malfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of ischemic cardiac malfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ischemic cardiac malfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1683337